Recently, the results of the OlympiA randomized phase III trial showed that adjuvant olaparib significantly improved overall survival as well as invasive disease-free survival and distant disease-free survival in patients with gBRCA and high-risk HER2-negative early breast cancer [14]. Here, ERBB2 is linked to breast cancer.